• Home
  • HK inno. N Coorporation

HK inno. N Coorporation

About HK inno. N Coorporation

HK inno.N is becoming a global No.1 pharmaceutical player in the global market by expanding exports and strengthening local business.A global pharmaceutical company that the world market watches Based on global sales and marketing competences that have been accumulated for years, we have rolled out the ethical drugs, active pharmaceutical ingredient (API), and Health & Beauty products across the g...

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • KR
  • 2020
    On CPHI since
Company types
Pharmaceutical company
View company profile
Contact info
  • Pine Avenue Tower A, 100 , Eulji-ro, 04551, Seoul, Korea, Republic Of
Show contact info Hide contact info

Products from HK inno. N Coorporation (3)

  • Tegoprazan

    Product Tegoprazan

    Tegoprazan is a novel patented Potassium-Competitive Acid Blocker (P-CAB) which alleviates the limitations of the historical Proton Pump Inhibitors (PPIs) and of other competing P-CABs. 

    Tegoprazan's competitive advantages have been demonstrated via Phase 3 clinical studies conducted in Korea a...
  • Atomet XR Tab. (Atorvastatin + Metformin)

    Product Atomet XR Tab. (Atorvastatin + Metformin)

    Fixed Dose Combination drug, indicated for Type2 Diabetes with Hyperlipidemia with Clinical trials phase Ⅰ & Ⅲ

  • Calmtop RTU Inj. (Irinotecan)

    Product Calmtop RTU Inj. (Irinotecan)

    Colorectal cancer

HK inno. N Coorporation Resources (1)

  • HK inno.N Corporation receives regulatory approval for first novel drug

    News HK inno.N Corporation receives regulatory approval for first novel drug

    Korean pharmaceutical firm HK inno.N Corp. said on Friday that its gastroesophageal reflux disease drug K-CAB has been approved by the Ministry of Food and Drug Safety, marking the first time for the company to launch an independently-developed novel drug under its name. HK inno.N plans to advance into overseas markets with its first novel drug, which has already been licensed out to China’s Shandong Luoxin Pharmaceutical Group in a 100 billion won ($89.7million)
    24 Sep 2020